Some of these drugs also demonstrate complementary anti-tumor effects when combined with chemotherapy, tyrosine kinase inhibitors, and immunotherapy, suggesting the additive benefit of co-targeting STAT3 in these settings. Here, STAT3 is linked to neoplasm.